ORG-34517

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H30O4
Molecular Weight	430.5354
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C3=CC=C4OCOC4=C3)C5=C6CCC(=O)C=C6CC[C@@]25[H]

InChI

InChIKey=DFELGYQKEOCHOA-BZAFBGKRSA-N

InChI=1S/C28H30O4/c1-3-11-28(30)12-10-23-21-7-4-17-13-19(29)6-8-20(17)26(21)22(15-27(23,28)2)18-5-9-24-25(14-18)32-16-31-24/h5,9,13-14,21-23,30H,4,6-8,10,12,15-16H2,1-2H3/t21-,22+,23-,27-,28-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C28H30O4
Molecular Weight	430.5354
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT03548714 | https://clinicaltrials.gov/ct2/show/NCT00226278 | https://www.ncbi.nlm.nih.gov/pubmed/26143299 | https://adisinsight.springer.com/drugs/800015251

ORG-34517 (or PT 150), a glucocorticoid receptor antagonist was development by Organon for the treatment of depression. This drug has completed phase II clinical trial for patients with major depression with psychotic features, however, this study was discontinued. In addition, Pop Test Cortisol LLC is developing ORG-34517 for the treatment of alcoholism. Now, this drug is in phase I clinical trial on stage recruiting to evaluate its safety when it is taken concurrently with alcohol.

Originator

Approval Year

PubMed

Title	Date	PubMed
Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line.	2008 Dec	19120154
Acute oral administration of the novel, competitive and selective glucocorticoid receptor antagonist ORG 34517 reduces the severity of ethanol withdrawal and related hypothalamic-pituitary-adrenal axis activation.	2015 Sep 1	26143299
CRF(1) but not glucocorticoid receptor antagonists reduce separation-induced distress vocalizations in guinea pig pups and CRF overexpressing mouse pups. A combination study with paroxetine.	2017 Mar	28089628

Patents

Sample Use Guides

In Vivo Use Guide

Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times. Intervention 1 includes PT150 (ORG-34517) with alcohol consumption

Route of Administration: Topical

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:24:58 GMT 2023` Edited by `admin` on `Fri Dec 15 16:24:58 GMT 2023`
Record UNII	17VAN37K4Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ORG-34517

Code

English

ORG34517

Code

English

PT150

Code

English

SCH-900636

Code

English

PT-150

Code

English

ESTRA-4,9-DIEN-3-ONE, 11-(1,3-BENZODIOXOL-5-YL)-17-HYDROXY-17-(1-PROPYN-1-YL)-, (11.BETA.,17.BETA.)-

Common Name

English

Code System Code Type Description

SMS_ID

100000178427